Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Thursday, January 27, 2022
The combination of the tyrosine kinase inhibitor neratinib, the estrogen receptor antagonist fulvestrant, and the monoclonal antibody trastuzumab may prove to be an effective treatment for patients with hormone receptor–positive, HER2-mutant metastatic breast cancer who had previously been treated with CDK4/6 inhibitors. Additionally, neratinib plus trastuzumab showed “encouraging activity” in HER2-mutated triple-negative breast cancer, according to Komal Jhaveri, MD, FACP, of Memorial Sloan Kettering Cancer Center, New York, and colleagues. The results of the open-label, multicenter, phase II SUMMIT trial were presented during the 2021 San Antonio Breast Cancer Symposium (SABCS; Abstract GS4-10).
Confirmed objective response rate and overall response rate were the primary and secondary outcomes, respectively. A total of 24 patients in a nonrandomized cohort received the neratinib, fulvestrant, and trastuzumab combination. A second cohort of 17 patients with HER2-mutant triple-negative breast cancer received neratinib plus trastuzumab. Mandatory loperamide prophylaxis was instituted during the first two treatment cycles.
The confirmed objective response rate was 46% for patients treated with the triplet regimen and 29% for patients treated with the doublet regimen. Overall response rates were 46% and 29%, respectively. Diarrhea was the most frequently reported treatment-related adverse event, with 96% of the triplet cohort and 94% of the doublet cohort experiencing diarrhea of grade 3 or below.
Disclosure: For full disclosures of the study authors, visit sabcs.org.
2021 San Antonio Breast Cancer Symposium
JNCCN Spotlights
